Sort
23,748 grants matching “melanoma”
Non-deletional CD8 T cell self-tolerance
$362,126Stephen C Jameson · University Of Minnesota · P01 · FY2019 · AI
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk
$362,119David E Fisher · Massachusetts General Hospital · R01 · FY2020 · AR
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk
$362,119David E Fisher · Massachusetts General Hospital · R01 · FY2018 · AR
MITF: master regulator of melanocyte development, pigmentation, and UV-related skin disease risk
$362,119David E Fisher · Massachusetts General Hospital · R01 · FY2019 · AR
Addressing Urban Rural Disparities in Cancer: The Case for Registry Expansion
$362,107Cathy J. Bradley · University Of Colorado Denver · R01 · FY2021 · CA
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblastoma
$362,088Roel Gw Verhaak · Jackson Laboratory · R01 · FY2017 · CA
Systematic identification of astrocyte-tumor crosstalk regulating brain metastatic tumors
$362,043Stephen Tc Wong · Methodist Hospital Research Institute · R01 · FY2022 · CA
Systematic identification of astrocyte-tumor crosstalk regulating brain metastatic tumors
$362,043Stephen Tc Wong · Methodist Hospital Research Institute · R01 · FY2023 · CA
Defining critical aspects of environmental ultraviolet exposure in melanogenesis
$361,969Myles G Cockburn · University Of Southern California · R01 · FY2010 · ES
Role of exosomal SPHK1 in ovarian cancer progression
$361,942Sunila Pradeep · Medical College Of Wisconsin · R01 · FY2025 · CA
Mechanisms of PAK1 activation, signaling and tumor resistance
$361,887Channing J Der · Univ Of North Carolina Chapel Hill · R01 · FY2015 · CA
Systemic RNA interference to reactivate p53 tumor suppression
$361,766Alexander H. Stegh · Northwestern University At Chicago · R01 · FY2018 · CA
Mechanisms of selective therapeutic synergy of PARP-inhibition and CTLA4 blockade engaged by interferon-gamma in the ovarian tumor microenvironment
$361,703Sarah Foster Adams · University Of New Mexico Health Scis Ctr · R37 · FY2019 · CA
Improved therapy for p53wt melanoma by functionally restoring the CDKN2A pathway
$361,688Ann Richmond · Vanderbilt University · R01 · FY2019 · CA
Mitf: A Master Gene for Melanocyte Development
$361,630David E Fisher · Dana-Farber Cancer Inst · R01 · FY2007 · AR
The role of RB in the retina & other tissues
$361,600James W Harbour · Washington University · R01 · FY2008 · EY
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
$361,558Charles J Dimitroff · Brigham And Women'S Hospital · R01 · FY2017 · CA
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
$361,558Charles J Dimitroff · Brigham And Women'S Hospital · R01 · FY2016 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
$361,468Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2024 · CA
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer
$361,444James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
The role of GPSM3 in tumor-promoting emergency myelopoiesis
$361,425Bin Zhang · Northwestern University At Chicago · R01 · FY2020 · CA
The role of GPSM3 in tumor-promoting emergency myelopoiesis
$361,425Bin Zhang · Northwestern University At Chicago · R01 · FY2021 · CA
Regulation of Human Tumorigensis by Cancer Specific NXF1 Adaptor Proteins
$361,425George L Sen · University Of California, San Diego · R01 · FY2022 · CA
Regulation of Human Tumorigensis by Cancer Specific NXF1 Adaptor Proteins
$361,425George L Sen · University Of California, San Diego · R01 · FY2025 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$361,357Ann Richmond · Vanderbilt University · R01 · FY2024 · CA